Oscient reiterated at market outperform by JMP

Oscient Pharmaceuticals Corp. was reiterated at a market outperform rating and $3 price target by JMP Securities analyst Adam Cutler. JMP Securities said it is tracking weekly prescriptions volumes of drugs Factive and Testim. For the week ending Sept. 30, Factive prescriptions represented 0.64% of the weekly prescriptions in the quinolone class, compared to 0.58% in the previous week. In May, Oscient began marketing Testim, a testosterone gel product and prescriptions for that drug also are on the rise. Shares of the Waltham, Mass.-based company were down $0.01, or 0.55%, at $1.81 on volume of 190,403 shares versus the three-month running average of 743,595 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.